PsiThera to Participate in Piper Sandler Virtual Novel Targets in Immunology SymposiumWATERTOWN, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PsiThera, Inc. today announced that Chief Executive Officer Eric Shaff, Founder and Chief Innovation Officer Woody Sherman, Ph.D., and Chief Scientific Officer Camil Sayegh, Ph.D., will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium being held on Friday, February 13, 2026, from 9:00 AM to 9:25 AM ET.
PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I TargetsWATERTOWN, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained by injectable-only approaches, announced today that it has closed a $47.5 million Series A financing and appointed Eric Shaff as Chief Executive Officer. The equity round was led by Samsara Biocapital and Lightstone Ventures with participation from other top-tier investors, including Roivant, YK Bioventures, Eurofarma Ventures, and others. PsiThera, formerly called Psivant Therapeutics, originated as a Roivant spinout and now operates as a fully independent company.
